We are live on ! Find out more
REPL icon

Replimune Group

135 hedge funds and large institutions have $1.29B invested in Replimune Group in 2022 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 62 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,989% more call options, than puts

Call options by funds: $4.34M | Put options by funds: $27K

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

158% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 24

133% more funds holding in top 10

Funds holding in top 10: 37 (+4)

83% more capital invested

Capital invested by funds: $704M → $1.29B (+$587M)

27% more funds holding

Funds holding: 106135 (+29)

14.22% more ownership

Funds ownership: 82.66%96.88% (+14%)

Holders
135
Holders Change
+29
Holders Change %
+27.36%
% of All Funds
2.17%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.11%
New
33
Increased
62
Reduced
24
Closed
4
Calls
$4.34M
Puts
$27K
Net Calls
+$4.32M
Net Calls Change
+$1.57M

REPL Hedge Fund Activity: Q4 2022 in Review

135 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q4 2022, worth a combined $1.29B — up 83% from $704M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new REPL positions and 4 closed out — a net gain of 29 holders — while 62 added to existing stakes and 24 trimmed.

The largest buyer was Redmile Group, adding an estimated $24.7M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $21M.

  • 135 institutional investors held Replimune Group (REPL) as of Q4 2022, up from 106 in Q3 2022.
  • Funds reported $1.29B of Replimune Group stock for Q4 2022, up 83% quarter-over-quarter.
  • 33 funds opened new Replimune Group positions in Q4 2022 and 4 closed out, a net change of +29 holders.
  • The largest Replimune Group buyer in Q4 2022 was Redmile Group, an estimated $24.7M added.
  • The largest Replimune Group seller in Q4 2022 was Atlas Venture Life Science Advisors, an estimated $21M sold.

Based on aggregated 13F filings for Q4 2022.